Preexposition Prophylaxis With Truvada (Tenofovir/Emtricitabine) as Potential Cause of Celiac Disease-Like Enteropathy.

Autor:	Pokryszka J; Department of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria.; Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Wichlas M; Gruppenpraxis Interne Donaustadt, Vienna, Austria., Vogelsang H; Department of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria., Trauner M; Department of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria., Herac-Kornauth M; Clinical Institute of Pathology, Medical University of Vienna, Wien, Austria., Kazemi-Shirazi L; Department of Gastroenterology and Hepatology, Medical University of Vienna, Wien, Austria.
Jazyk:	angličtina
Zdroj:	Zeitschrift fur Gastroenterologie [Z Gastroenterol] 2024 Mar; Vol. 62 (3), pp. 404-406. Date of Electronic Publication: 2023 May 15.
DOI:	10.1055/a-2079-6445
Abstrakt:	We present here a case of a 39-year-old patient who presented with celiac-disease-like symptoms and MARSH 3a histology in duodenal biopsies under normal diet. Interestingly, HLA genotyping and celiac-specific serology were negative, primarily leading to exclusion of celiac disease. However, biopsies from a second endoscopy a couple of months later (still under normal diet) showed histologic progression of the disease to MARSH 3b and led to the re-evaluation of the out-of-hospital-obtained histological samples by a pathologist experienced in celiac disease. The second biopsy described previously as MARSH 3b turned out to be non-specific and was therefore re-classified as MARSH 0. After all known causes of duodenal villous atrophy were excluded by a thorough evaluation, a correlation between the first biopsy (MARSH 3a) and Truvada intake could be established. After Truvada discontinuation and under normal diet, normalisation of duodenal mucosa was observed, leading to the assumption that Truvada could lead to celiac-like enteropathy. Competing Interests: JP: no conflicts of interest MW: no conflicts of interest HV: no conflicts of interest MT: speaker for Falk Foundation, Gilead, Intercept and MSD; advised for Albireo, BiomX, Boehringer Ingelheim, Falk Pharma GmbH, Genfit, Gilead, Intercept, Jannsen, MSD, Novartis, Phenex, Regulus and Shire. Travel grants from Abbvie, Falk, Gilead and Intercept and research grants from Albireo, Alnylam, Cymabay, Falk, Gilead, Intercept, MSD Takeda and UltraGenyx. He is also co-inventor of patents on the medical use of NorUDCA filed by the Medical Universities of Graz and Vienna. LKS: has been a principal investigator for studies sponsored by SigmaTau, Sanofi, Tigenix and FALK; has received lecture feesfrom MSD, AbbVie, Ferring, MerckSerono/Dr Falk, Chiesi, Novartis, Roche, Abbott, Phadia Austria/Thermo Fisher Scientific, CSL-Behring , Janssen-Cilag Pharma, Vertex; has received non-financial support from Mylan, Abbott, MSD, Gilead, MerckSerono/Dr Falk, Novartis, Pfizer, Janssen-Cilag Pharma, Chiesi, Shire, Abbvie, Takeda, Vertex, Astropharma; has been a consultant for MSD and Takeda MHK: no conflicts of interest (The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu